Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of sabatolimab (MBG453) plus azacitidine versus placebo plus azacitidine in higher-risk MDS or CMML-2
MOH_2020-03-24_008797Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) comparing sabatolimab + azacitidine with placebo + azacitidine (2 arms). Started Mar 2020; status: active, not recruiting.
02
Drugs
sabatolimabazacitidine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on MOH_2020-03-24_008797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-03-24_008797.